Amryt Pharma (Amryt Pharma) Total Assets : $736.9 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Total Assets?

Amryt Pharma's Total Assets for the quarter that ended in Sep. 2022 was $736.9 Mil.

Warning Sign:

If a company builds assets at 74.3% a year, faster than its revenue growth rate of 67.4% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Amryt Pharma's average Total Assets Growth Rate was -10.70% per year. During the past 3 years, the average Total Assets Growth Rate was 114.80% per year. During the past 5 years, the average Total Assets Growth Rate was 74.30% per year. During the past 10 years, the average Total Assets Growth Rate was 110.30% per year.

During the past 12 years, Amryt Pharma's highest 3-Year average Total Assets Growth Rate was 636.00%. The lowest was 8.90%. And the median was 79.60%.

Total Assets is connected with ROA %. Amryt Pharma's annualized ROA % for the quarter that ended in Sep. 2022 was -11.08%. Total Assets is also linked to Revenue through Asset Turnover. Amryt Pharma's Asset Turnover for the quarter that ended in Sep. 2022 was 0.08.

Amryt Pharma Total Assets Historical Data

The historical data trend for Amryt Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Total Assets Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

Get a 7-Day Free Trial

96.08

80.83

527.10

536.59

816.06

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Assets	Get a 7-Day Free Trial															855.46	816.06	786.87	764.74	736.88

Amryt Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Amryt Pharma's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	356.661	+	459.396
	=	816.1

Amryt Pharma's Total Assets for the quarter that ended in Sep. 2022 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2022 )	+	Total Liabilities (Q: Sep. 2022 )
	=	324.277	+	412.598
	=	736.9

Amryt Pharma (NAS:AMYT) Total Assets Explanation

Total Assets is connected with ROA %.

Amryt Pharma's annualized ROA % for the quarter that ended in Sep. 2022 is

ROA %	=	Net Income (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
	=	-83.18	/	( (764.744	+	736.875)	/ 2 )
	=	-83.18	/	750.8095
	=	-11.08 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Amryt Pharma's Asset Turnover for the quarter that ended in Sep. 2022 is

	Asset Turnover
=	Revenue (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
=	61.126	/	( (764.744	+	736.875)	/ 2 )
=	61.126	/	750.8095
=	0.08

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Amryt Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).